Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | IGF1R | P08069 | 6/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10133723 | 0.77 | MAPT (0.68) | MAPTIGF1RDRD2DRD3TLR7 | |
| SCHEMBL13940133 | 0.75 | MAPT (0.72) | MAPTIGF1RTLR7ADORA2AADORA1 | |
| SCHEMBL22275078 | 0.74 | IGF1R (0.63) | MAPTIGF1RNPSR1LMNAHTT | |
| SCHEMBL7693307 | 0.74 | MAPT (0.68) | MAPTIGF1RDRD2DRD3TLR7 | |
| SCHEMBL18499105 | 0.72 | CYP2C9 (0.63) | MAPTIGF1RTLR7ADORA2AADORA1 | |
| SCHEMBL10113543 | 0.72 | MAPT (0.61) | MAPTDRD2DRD3TLR7CYP2C9 | |
| SCHEMBL9999685 | 0.72 | MAPT (0.64) | MAPTIGF1RTLR7ADORA2AADORA1 | |
| SCHEMBL10113816 | 0.72 | MAPT (0.60) | MAPTIGF1RDRD2DRD3TLR7 | |
| SCHEMBL11934977 | 0.71 | MAPT (0.60) | MAPTTLR7ADORA2AADORA1KMT2A | |
| SCHEMBL15917480 | 0.70 | MAPT (0.54) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198254-A1 | Polyamide analogs | GENELABS TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | claimed |
| US-20020198254-A1 | Polyamide analogs | GENELABS TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198254-A1 | Polyamide analogs | CYP51A1, HDAC6, ERG28 | MAPT 2074/4885IGF1R 4036/4885DRD2 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.